⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385876 | 0.87 | — | — | |
| SCHEMBL724148 | 0.79 | — | — | |
| SCHEMBL386987 | 0.78 | — | — | |
| SCHEMBL217699 | 0.74 | — | — | |
| SCHEMBL20515207 | 0.74 | — | — | |
| SCHEMBL20515219 | 0.74 | — | — | |
| SCHEMBL1039848 | 0.72 | — | — | |
| SCHEMBL7236913 | 0.71 | — | — | |
| SCHEMBL8781811 | 0.71 | — | — | |
| SCHEMBL20240669 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370206-A1 | ESTERS OF 7-COOH CBD DERIVATIVES AND THEIR USE AS PREVENTION, PROPHYLAXIS OF PROGRESSION, AND/OR TREATMENT OF NEUROGENERATIVE DISEASES | Receptorpharma Inc S-Corp (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024099364-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | LAEKNA THERAPEUTICS SHANGHAI CO., LTD. (CN) | 2024-05-16 | — | — | WO | claimed |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | claimed |
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | claimed |
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | claimed |
| WO-2023220219-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | claimed |
| EP-4244213-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| CN-116745288-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2016128365-A1 | SUBSTITUTED 1-CYCLOALKYL-2-OXOTETRAHYDROQUINOLIN-6-YL-SULFONAMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | WO | claimed |
| US-9376396-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-28 | — | — | US | claimed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | claimed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | claimed |
| EP-2909201-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-26 | — | — | EP | claimed |
| US-20140194437-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-10 | — | — | US | claimed |
| WO-2014064038-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-01 | — | — | WO | claimed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | claimed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | claimed |